Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P0CG22

UPID:
DR4L1_HUMAN

ALTERNATIVE NAMES:
Short chain dehydrogenase/reductase family 25C member 4

ALTERNATIVE UPACC:
P0CG22

BACKGROUND:
Putative dehydrogenase/reductase SDR family member 4-like 1, also known as Short chain dehydrogenase/reductase family 25C member 4, plays a putative role as an oxidoreductase. This classification hints at its involvement in essential biochemical pathways, including those related to the reduction and oxidation processes vital for cellular energy dynamics and integrity.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Putative dehydrogenase/reductase SDR family member 4-like 1 unveils potential avenues for therapeutic intervention. Given its central role in redox reactions, targeting this protein could lead to innovative treatments, especially in diseases where redox imbalances are a contributing factor.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.